Compare SHEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | EVO |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.1M | 994.5M |
| IPO Year | 1994 | N/A |
| Metric | SHEN | EVO |
|---|---|---|
| Price | $14.16 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $26.00 | $7.00 |
| AVG Volume (30 Days) | ★ 266.7K | 28.6K |
| Earning Date | 05-01-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $7.12 | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $2.31 |
| 52 Week High | $17.35 | $4.42 |
| Indicator | SHEN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 37.20 |
| Support Level | $14.10 | $2.32 |
| Resistance Level | $14.47 | $3.82 |
| Average True Range (ATR) | 0.64 | 0.07 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 5.57 | 0.00 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.